MétaCan
Menu
Back to cohort
Record W2808415597 · doi:10.1016/s1473-3099(18)30292-5

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

2018· review· en· W2808415597 on OpenAlexaff
Natalie I Mazur, Deborah Higgins, Marta C. Nunes, Jose ́A. Melero, Annefleur C Langedijk, Nicole Horsley, Ursula J. Buchholz, Peter Openshaw, Jason S. McLellan, Janet A. Englund, Asunción Mejías, Ruth A. Karron, Eric A. F. Simões, Ivana Knežević, Octavio Ramilo, Pedro A. Piedra, Helen Y. Chu, Ann R. Falsey, Harish Nair, Leyla Kragten‐Tabatabaie, Anne Greenough, Eugenio Baraldi, Nikolaos G. Papadopoulos, Johan Vekemans, Fernando P. Polack, Ashish Satav, Edward E. Walsh, Renato T. Stein, Barney S. Graham, Louis Bont

Bibliographic record

VenueThe Lancet Infectious Diseases · 2018
Typereview
Languageen
FieldMedicine
TopicRespiratory viral infections research
Canadian institutionsCentre for Global Health Research
FundersNHLBI Division of Intramural ResearchJanssen PharmaceuticalsNational Institute of Allergy and Infectious DiseasesJohnson and JohnsonMedical Research CouncilMerckManchester Biomedical Research CentreBritish Society for ImmunologySanofi PasteurInnovative Medicines InitiativeDivision of Intramural Research, National Institute of Allergy and Infectious DiseasesNational Institute for Health and Care ResearchNational Institutes of HealthNovavaxWorld Health OrganizationWellcome TrustGilead SciencesNovartisAbbVieEuropean CommissionSanofiGlaxoSmithKlineAstraZenecaPfizerBill and Melinda Gates Foundation
KeywordsMedicineVirologyVirusMonoclonal antibodyClinical trialDiseaseImmunologyIntensive care medicineAntibody

Abstract

fetched live from OpenAlex

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0000.001
Scholarly communication0.0010.002
Open science0.0010.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.093
GPT teacher head0.416
Teacher spread0.323 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations474
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueThe Lancet Infectious DiseasesSame topicRespiratory viral infections researchFrench-language works237,207